U.S. Pharma Stock News

If you are wondering whether FormFactor's current share price lines up with its underlying worth, this article will walk you through what the numbers are actually saying. The stock recently closed at US$92.22, with returns of 2.6% over 7 days, a 2.5% decline over 30 days, 55.8% year to date and 196.4% over 1 year that may catch your eye. Recent coverage has focused on FormFactor as a semiconductor testing specialist, with investors watching how its technology and customer exposure position...

Hubbell (HUBB) is back in focus after management used the JPMorgan Industrials Conference on March 18 to outline a constructive first quarter outlook, highlighting strong demand across utility, data center, and light industrial markets. See our latest analysis for Hubbell. The share price has eased back recently with a 9.68% 1 month share price return and a 3.43% 1 day move lower to US$475.74. However, the 1 year total shareholder return of 42.35% and 5 year total shareholder return of...

Genpact (G) has been catching investor attention after recent share price swings, with the stock now trading around $38.70. That move comes alongside mixed short term returns and weaker performance over the past year. See our latest analysis for Genpact. These short term share price moves sit against a weaker picture over longer periods, with a 90 day share price return of a 20.21% decline and a 1 year total shareholder return of a 21.15% decline, which suggests recent optimism is still...

TG Therapeutics, ticker NasdaqCM:TGTX, announced a new five year, $750 million senior secured credit facility with Blue Owl Capital. The agreement is described as non dilutive, meaning it does not involve issuing new equity to raise capital. The facility includes repayment of prior debt and could expand to as much as $1b in total available financing. TG Therapeutics focuses on developing and commercializing therapies in the biopharmaceutical space, where access to sizeable, flexible capital...

If you are wondering whether Modine Manufacturing at around US$196.55 still offers value after a major price increase, or if you might be late to the story, this article breaks down what the current price reflects. The stock has seen a 4.2% gain over the last 7 days, a 13.2% decline over 30 days, a 39.6% return year to date, and a 121.9% return over the past year. These moves naturally raise questions about both upside potential and changing risk. Recent coverage has focused on Modine as a...

Senior UK bankers are reported to be exploring a domestic payment system that would operate independently of Mastercard and Visa. The proposed sovereign network would handle card payments within the UK using homegrown infrastructure. This effort is framed as part of a broader push for payment sovereignty and could affect international schemes like NYSE:MA if it progresses. For Mastercard (NYSE:MA), the UK is an important international market where it provides card processing and related...

Recent share performance and business scale Zions Bancorporation National Association (ZION) has drawn investor attention after a recent stretch of mixed share performance, including a 13.5% decline over the past month and a 10.2% decline in the past 3 months. Over a longer horizon, the stock shows a 12.8% total return over the past year and a multi year total return above 7x. The company reports annual revenue of US$3.3b and net income of US$884 million. See our latest analysis for Zions...

For readers considering whether Kyndryl Holdings at around US$12.21 is starting to look like value or remains a stock to approach with caution, this article breaks down what the current price may be implying. The shares have faced heavy pressure, with a 1 year return of 64.7% and a year to date move of 52.1%. This naturally raises questions about both potential upside and perceived risk. Recent coverage has focused on how Kyndryl continues to trade as a stand alone IT services provider after...

Arthur J. Gallagher & Co. reported that director Sherry Barrat informed the company on March 6, 2026 of her decision to retire from the Board, effective May 12, 2026, after which the Board will shrink from ten to nine members. Her retirement, alongside recent analyst commentary, sharpens investor focus on how board composition and external views may shape oversight of the company’s ongoing growth plans and risk management priorities. We’ll now examine how RBC’s renewed positive coverage,...

If you are wondering whether MakeMyTrip at around US$39.78 is starting to look like value or still carries more risk than reward, you are not alone. The stock has seen sharp moves, with returns of 12.6% decline over 7 days, 29.0% decline over 30 days, 51.4% decline year to date and 60.6% decline over 1 year, even though the 3 year and 5 year returns sit at 65.3% and 23.7% respectively. Recent coverage has focused on how this volatility affects sentiment toward online travel platforms and...

Investors may be wondering whether Progress Software's current share price reflects its true value, or if the recent weakness is opening up an opportunity. The stock closed at US$31.29, with returns of an 8.8% decline over 7 days, a 22.4% decline over 30 days, a 23.8% decline year to date, and a 42.5% decline over 1 year. These moves may have shifted how the market views its risk and reward trade off. Recent headlines have focused on Progress Software's role as a software provider and how...

Roku stock snapshot after recent performance swings Roku (ROKU) has been trading through mixed recent moves, with a 2.7% decline over the past day, a small gain over the past week, and a roughly 15% drop in the past 3 months. See our latest analysis for Roku. Roku’s recent 1 month share price return of 4.73% contrasts with a 90 day share price decline of 15.05%. The 1 year total shareholder return of 19.13% points to stronger past rewards than the 5 year total shareholder return, which is...

Blackstone (BX) is in focus after reports that it has limited redemptions from certain private debt funds, alongside peers like BlackRock and Morgan Stanley, as concerns about private credit and AI related default risks build. See our latest analysis for Blackstone. At a share price of US$110.43, Blackstone’s 90 day share price return of 29.13% and year to date share price return of 30.46% mark a sharp pullback. However, the 3 year total shareholder return of 44.39% and 5 year total...

If you are wondering whether e.l.f. Beauty is attractively priced or just riding a wave of enthusiasm, the current share price of US$72.50 makes that a timely question. The stock has recently seen a 1.2% decline over the last week, a 22.9% decline over the past month, yet is still up 15.4% over the last year and 167.4% over five years, which can change how risk and return feel for new and existing shareholders. Recent coverage has focused on e.l.f. Beauty as a prominent name in the US beauty...

Why Upwork Stock Is Drawing Attention Now Upwork (UPWK) is back on many watchlists after a stretch of weak returns, including a 47% decline over the past 3 months. This has prompted investors to reassess its recent financial profile. See our latest analysis for Upwork. The recent 47% 90 day share price decline, on top of a 43% year to date share price return and a 17% 1 year total shareholder return, suggests momentum has been fading as investors reassess both growth prospects and risks...

Sionna Therapeutics (SION) is back in focus for investors after recent trading left the shares with a return of about 166% over the past year, contrasting with weaker near term moves. See our latest analysis for Sionna Therapeutics. The share price is currently US$36.39, and short term share price returns over 1 and 3 months have been weak, yet the 1 year total shareholder return of about 166% points to strong earlier momentum that has recently cooled. If you are looking beyond a single...

Hamilton Lane (NasdaqGS:HLNE) has partnered with CenterSquare Investment Management to recapitalize Tenaya Village, a suburban Las Vegas retail center. The firm becomes the asset's majority investor, expanding its role in GP led secondary deals tied to essential service retail. The transaction signals active interest in real assets and alternative deal structures beyond traditional private credit and fund vehicles. Hamilton Lane enters this deal with its shares at $99.59 and a mixed return...

If you are wondering whether Walker & Dunlop at around US$43.82 is starting to look like value, the recent share performance gives plenty to think about. The stock has seen a 2.6% decline over the past week, a 30.7% decline over the last month, and returns of 25.4% year to date and 46.7% over the past year, with a 33.2% and 51.6% decline over the last 3 and 5 years respectively. These moves have put valuation front and center for many investors who are reassessing what they are willing to...

If you are wondering whether RPC at US$6.83 is priced attractively or not, the starting point is understanding what the current market price might be implying about its future. Over the short term, the stock has returned 4.8% in the last 7 days, 12.0% over 30 days, 23.5% year to date, 28.6% over 1 year, and 38.1% over 5 years, while the 3 year return sits at a 4.0% decline. Recent coverage around RPC has focused on how investors are reassessing energy service providers, with attention on...

Sigma Lithium (NasdaqCM:SGML) has resumed industrial scale sales of premium lithium concentrate. The company has completed its first major sale of high purity lithium fines. The transaction covers 400,000 tonnes of premium lithium fines at a fixed price. Management highlights this as opening up significant new profit streams and improving sales visibility. Sigma Lithium, a producer of battery grade lithium materials, now has fresh evidence of executed sales to match the attention around its...

Vaxcyte recently reported in The Lancet Infectious Diseases that its 31-valent pneumococcal conjugate vaccine candidate VAX-31 showed strong immune responses and a safety profile similar to Prevnar 20 in a Phase 1/2 study of 1,015 adults aged 50 and older, and has since advanced the high-dose regimen into the OPUS Phase 3 adult program. An important insight from these data is that VAX-31 met or exceeded regulatory immunogenicity criteria for all 31 serotypes at higher doses while covering...

For investors wondering whether Mirion Technologies at around US$18.45 offers real value or is mainly driven by headline excitement, this article walks through what the current price might be implying about the business. The stock has slipped around 1.3% over the last week and 13.3% over the last month, even though the 1 year return sits at 21.2% and the 3 year return reflects a very large gain from earlier levels. Recent coverage has focused on Mirion Technologies as a specialist in...

In March 2026, Advanced Energy Industries, Inc. launched the LPP200 series of 200 W ultra-low-profile AC-DC power supplies, offering 0.75-inch height, 12–48 V outputs, and dual medical (EN/IEC/cUL60601-1, Type BF) and industrial (EN/IEC/cUL62368) certifications for compact medical and industrial devices. The LPP200 series’ combination of high power density, strong EMI/EMC performance, and medically certified ultra-thin design could make Advanced Energy more relevant in space-constrained...

On February 26, 2026, Universal Display Corporation announced that it had extended its long-term OLED material supply and license agreements with LG Display, covering continued access to its UniversalPHOLED technologies for TVs, monitors, mobile devices, and automotive panels. This renewed partnership underlines Universal Display’s entrenched role in LG Display’s OLED roadmap, reinforcing its position as a key technology and materials provider across multiple high-performance display...